358
Views
11
CrossRef citations to date
0
Altmetric
Drug Evaluation

Lesinurad for the treatment of hyperuricaemia in people with gout

&
Pages 1875-1881 | Received 12 Sep 2017, Accepted 02 Nov 2017, Published online: 13 Nov 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Naoyuki Otani, Motoshi Ouchi, Hideo Kudo, Shuichi Tsuruoka, Ichiro Hisatome & Naohiko Anzai. (2020) Recent approaches to gout drug discovery: an update. Expert Opinion on Drug Discovery 15:8, pages 943-954.
Read now
Larysa Strilchuk, Federica Fogacci & Arrigo Fg Cicero. (2019) Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opinion on Drug Safety 18:4, pages 261-271.
Read now

Articles from other publishers (9)

M.V. Tkachenko, M.Yu. Babanina, H.V. Volchenko, Ye.M. Kitura & O.A. Kyryan. (2023) MODERN VIEW ON ANTI-INFLAMMATORY AND URAT-LOWERING THERAPY FOR GOUT. Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 23:3, pages 217-224.
Crossref
A. A. Garanin, N. L. Novichkova & N. L. Novichkova. (2022) Prospects of anti-inflammatory and urate-lowering therapy of gout: A vector from the past to the future. Rheumatology Science and Practice 60:2, pages 205-213.
Crossref
Ze-an Zhao, Yu Jiang, Yan-yu Chen, Ting Wu, Qun-sheng Lan, Yong-mei Li, Lu Li, Yang Yang, Cui-ting Lin, Ying Cao, Ping-zheng Zhou, Jia-yin Guo, Yuan-xin Tian & Jian-xin Pang. (2021) CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia. Acta Pharmacologica Sinica 43:1, pages 121-132.
Crossref
Arrigo F. G. Cicero, Federica Fogacci, Masanari Kuwabara & Claudio Borghi. (2021) Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. Medicina 57:1, pages 58.
Crossref
Kenichi Furihata, Katsuaki Nagasawa, Atsushi Hagino & Yuji Kumagai. (2020) A drug–drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males. Clinical and Experimental Nephrology 24:S1, pages 36-43.
Crossref
Shuangshuang Zhang, Yong Wang, Jinsong Cheng, Ning Huangfu, Ruochi Zhao, Zhenyu Xu, Fuxing Zhang, Wenyuan Zheng & Dandan Zhang. (2019) Hyperuricemia and Cardiovascular Disease. Current Pharmaceutical Design 25:6, pages 700-709.
Crossref
Philip C. Robinson. (2018) Gout – An update of aetiology, genetics, co-morbidities and management. Maturitas 118, pages 67-73.
Crossref
Caroline L. Benn, Pinky Dua, Rachel Gurrell, Peter Loudon, Andrew Pike, R. Ian Storer & Ciara Vangjeli. (2018) Physiology of Hyperuricemia and Urate-Lowering Treatments. Frontiers in Medicine 5.
Crossref
Urspeter Masche. (2018) Lesinurad. pharma-kritik 40:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.